Are we ready for patient-reported outcomes in hepatocellular carcinoma? Comment

被引：0
作者：
Personeni, Nicola
Rimassa, Lorenza [1 ]
机构：
[1] Humanitas Univ, Dept Biomed Sci, I-20090 Milan, Italy
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2021年 / 6卷 / 08期
关键词：
MULTICENTER PHASE-III; 1ST-LINE 1L TREATMENT; QUALITY-OF-LIFE; NIVOLUMAB NIVO; SORAFENIB SOR; CHECKMATE; 459; PATIENTS PTS;
D O I：
10.1016/S2468-1253(21)00139-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：602 / 603
页数：3
相关论文
共 10 条
  • [1] EDELINE J, 2020, J CLIN ONCOL, V38, P483, DOI DOI 10.1200/JCO.2020.38.4_SUPPL.483
  • [2] European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
  • [3] Health-Related Quality of Life in Patients With Hepatocellular Carcinoma: A Systematic Review
    Fan, Sheng-Yu
    Eiser, Christine
    Ho, Ming-Chih
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (07) : 559 - 564
  • [4] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed O.
    Li, Daneng
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Liu, Juan
    Huang, Chen
    Mulla, Sohail
    Wang, Yulei
    Lim, Ho Yeong
    Zhu, Andrew X.
    Cheng, Ann-Lii
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) : 1894 - 1905
  • [5] Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey
    Gill, Jennifer
    Baiceanu, Andrei
    Clark, Paul J.
    Langford, Andrew
    Latiff, Julianah
    Yang, Pei-Ming
    Yoshida, Eric M.
    Kanavos, Panos
    [J]. FUTURE ONCOLOGY, 2018, 14 (17) : 1701 - 1710
  • [6] Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
    Kudo, Masatoshi
    Finn, Richard S.
    Qin, Shukui
    Han, Kwang-Hyub
    Ikeda, Kenji
    Piscaglia, Fabio
    Baron, Ari
    Park, Joong-Won
    Han, Guohong
    Jassem, Jacek
    Blanc, Jean Frederic
    Vogel, Arndt
    Komov, Dmitry
    Evans, T. R. Jeffry
    Lopez, Carlos
    Dutcus, Corina
    Guo, Matthew
    Saito, Kenichi
    Kraljevic, Silvija
    Tamai, Toshiyuki
    Ren, Min
    Cheng, Ann-Lii
    [J]. LANCET, 2018, 391 (10126) : 1163 - 1173
  • [7] Design and endpoints of clinical trials in hepatocellular carcinoma
    Llovet, Josep M.
    Di Bisceglie, Adrian M.
    Bruix, Jordi
    Kramer, Barnett S.
    Lencioni, Riccardo
    Zhu, Andrew X.
    Sherman, Morris
    Schwartz, Myron
    Lotze, Michael
    Talwalkar, Jayant
    Gores, Gregory J.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (10): : 698 - 711
  • [8] U.S. Food and Drug Administration, 2009, GUID DOC PAT REP OUT
  • [9] Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
    Vogel, Arndt
    Qin, Shukui
    Kudo, Masatoshi
    Su, Yun
    Hudgens, Stacie
    Yamashita, Tatsuya
    Yoon, Jung-Hwan
    Fartoux, Laetitia
    Simon, Krzysztof
    Lopez, Carlos
    Sung, Max
    Mody, Kalgi
    Ohtsuka, Tatsuroh
    Tamai, Toshiyuki
    Bennett, Lee
    Meier, Genevieve
    Breder, Valery
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (08): : 649 - 658
  • [10] Yau T, 2019, ANN ONCOL, V30, P874
1